Myfortic (mycophenolate sodium) delayed-release tablets.
Myfortic is a new formulation of mycophenolic acid (MPA) utilizing enteric coated mycophenolate sodium (EC-MPS) that may have fewer gastrointestinal side effects.
Qureshi
Ansa
A
Department of Dermatology, Columbia University, New York, NY, USA. NSS32@columbia.edu
Scheinfeld
Noah
N
D000014:Abnormalities, Drug-Induced / Q000209:etiology; D000022:Abortion, Spontaneous / Q000139:chemically induced; D000075202:Contraindications; D003692:Delayed-Action Preparations; D005260:Female; D005744:Gastric Acid; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007168:IMP Dehydrogenase / Q000037:antagonists & inhibitors; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D007408:Intestinal Absorption; D008297:Male; D009173:Mycophenolic Acid / Q000008:administration & dosage* / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D011247:Pregnancy; D011355:Prodrugs / Q000493:pharmacokinetics; D012871:Skin Diseases / Q000188:drug therapy; D013608:Tablets, Enteric-Coated
D003692:Delayed-Action Preparations; D007166:Immunosuppressive Agents; D011355:Prodrugs; D013608:Tablets, Enteric-Coated; D007168:IMP Dehydrogenase; D009173:Mycophenolic Acid